Physician profile
Manuel Katz
NPI 1376541359
$2,212.42
in general payments reported to CMS, 2019-2025
21 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $29.06 · 2021: $70.29 · 2022: $26.29 · 2023: $77.45 · 2024: $470 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $975 · Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $975.00 |
| Food and Beverage | $952.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $992.59 | 2025 | S-217622, Fetroja |
| Abbvie INC. | $486.45 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $97.98 | 2023-2025 | Dificid, Zerbaxa, Pifeltro |
| Lilly USA, LLC | $92.62 | 2024-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $84.48 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $68.43 | 2019-2020 | |
| Exact Sciences Corporation | $66.89 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $57.11 | 2019-2020 | |
| Viiv Healthcare Company | $37.45 | 2025 | Cabenuva, Dovato |
| Janssen Biotech, INC. | $37.05 | 2019 | |
| Convatec INC. | $26.26 | 2024 | |
| Abbott Laboratories | $24.16 | 2024 | Freestyle Libre |
| Amgen INC. | $18.60 | 2025 | Evenity |
| Melinta Therapeutics, LLC | $17.90 | 2025 | Rezzayo, Kimyrsa |
| Seqirus USA INC | $17.00 | 2024 | Fluad, Flucelvax |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16.52 | 2023 | Arexvy |
| Aimmune Therapeutics, INC. | $16.28 | 2024 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.40 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.87 | 2025 | Nuzyra |
| Scilex Pharmaceuticals INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.